Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Milena Music CGS-M Application
FY 2017-18
Summary
There is an unmet need for predictive biomarkers of response to cancer immunotherapy, as a one size fits all approach to cancer treatment has resulted in unsuccessful or inappropriate therapy. It is suggested that during effective immunotherapy, cancer cell death promotes the release of tumor-associated antigens (TAAs) into circulation, initiating a humoral immune response involving autoantibody production. A recent study showed that patients who responded positively to immunotherapy involving a monoclonal antibody against immune checkpoint molecule CTLA-4 developed enhanced antibody responses to an increased amount of autoantigens in comparison to non-responders. My project involves screening cancer patient serum, early in immune checkpoint blockade (ICB) therapy, to identify autoantibodies that can be informative of clinical response. The screening process will involve thousands of human protein antigens, representative of the human proteome. Characterization of autoantibody-bound antigens will be performed by immuno-mass spectrometry methods. Antibodies are excellent biomarkers since they are stable proteins that are easy to screen for, and are present in serum in higher levels than their corresponding antigens. I hypothesize that several antibodies against TAAs will be identified as biomarkers of response to ICB, with an increase in autoantibody titers correlating to the intensity of the anti-tumor immune response. This novel proteomics approach has the potential to identify biomarkers that will separate non-responders from responders early in treatment, sparing non-responders from serious toxicity. These biomarkers will ensure proper patient selection for therapy and save significant resources.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
386563
Name
Music Milena
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Milena Music CGS-M Application
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Clinical Response; Immune Checkpoint Blockade; Immunotherapy; Mass Spectrometry; Predictive Biomarkers; Proteomics; Serum Autoantibodies; Tumor-Associated Antigens
Abstract
There is an unmet need for predictive biomarkers of response to cancer immunotherapy, as a one size fits all approach to cancer treatment has resulted in unsuccessful or inappropriate therapy. It is suggested that during effective immunotherapy, cancer cell death promotes the release of tumor-associated antigens (TAAs) into circulation, initiating a humoral immune response involving autoantibody production. A recent study showed that patients who responded positively to immunotherapy involving a monoclonal antibody against immune checkpoint molecule CTLA-4 developed enhanced antibody responses to an increased amount of autoantigens in comparison to non-responders. My project involves screening cancer patient serum, early in immune checkpoint blockade (ICB) therapy, to identify autoantibodies that can be informative of clinical response. The screening process will involve thousands of human protein antigens, representative of the human proteome. Characterization of autoantibody-bound antigens will be performed by immuno-mass spectrometry methods. Antibodies are excellent biomarkers since they are stable proteins that are easy to screen for, and are present in serum in higher levels than their corresponding antigens. I hypothesize that several antibodies against TAAs will be identified as biomarkers of response to ICB, with an increase in autoantibody titers correlating to the intensity of the anti-tumor immune response. This novel proteomics approach has the potential to identify biomarkers that will separate non-responders from responders early in treatment, sparing non-responders from serious toxicity. These biomarkers will ensure proper patient selection for therapy and save significant resources.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Music, Milena
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~